MID-VOLUME · FEMALE-LED
lifitegrast Side Effects
lifitegrast (also sold as Xiidra) sits MID-VOLUME #265 of 524 by FAERS report count. Lead signal: FEMALE-LED - 83% of sex-coded reports are female (11,783 F / 2,442 M). Demographics and serious-outcome tables follow.
Data updated 2026-05-15
- 15,783
- FAERS reports
FDA Adverse Event Reporting System extract for lifitegrast. Stamp set WATCHLIST · DEATH-MARKED · HOSP-LIGHT. How figures are compiled.
lifitegrast reporting skew - 83% of sex-coded reports are female (11,783 F / 2,442 M). Volume band MID-VOLUME #265 of 524 by FAERS report count; caseload WATCHLIST.
Mid-book FAERS page for lifitegrast (Xiidra) (15,783 reports). Signature FEMALE-LED. Dominant age band on file: 45-64. Educational reference only.
Counts from the openFDA FAERS extract (2015–2025). Stamps WATCHLIST · DEATH-MARKED · HOSP-LIGHT · FEMALE-LED.
EYE IRRITATION leads 2,649 of 15,783 reports
FEMALE-LED reporters · age peak 45-64
Female-led reporters (83% of sex-coded rows)
Age peak 45-64 (1,693 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death appears on 283 reports (1.8% - MARKED). Reactions below co-occur in those rows only.
| Reaction | Reports |
|---|---|
| DEATH | 252 |
| FALL | 5 |
| HEADACHE | 4 |
| PNEUMONIA | 4 |
| ARTHRALGIA | 3 |
| BREAST CANCER | 3 |
| BREAST CANCER METASTATIC | 3 |
| INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION | 3 |
| SPEECH DISORDER | 3 |
| ACUTE KIDNEY INJURY | 2 |
| CARDIAC FAILURE CONGESTIVE | 2 |
| CEREBROVASCULAR ACCIDENT | 2 |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2 |
| DIABETES MELLITUS | 2 |
| DIARRHOEA | 2 |
| DYSPHAGIA | 2 |
| EYE PAIN | 2 |
| HEPATIC FAILURE | 2 |
Reactions in Hospitalization Reports
Hospitalization is lighter here (615). Reactions in that subset:
| Reaction | Reports |
|---|---|
| PNEUMONIA | 90 |
| FALL | 62 |
| FEELING ABNORMAL | 51 |
| ARTHRITIS | 50 |
| PLATELET COUNT DECREASED | 47 |
| BLOOD FOLATE DECREASED | 43 |
| HEADACHE | 40 |
| HOSPITALISATION | 40 |
| DYSPNOEA | 38 |
| COVID-19 | 36 |
| MALAISE | 36 |
| WHITE BLOOD CELL COUNT DECREASED | 36 |
| PAIN | 32 |
| DIZZINESS | 30 |
| NAUSEA | 27 |
| VISION BLURRED | 27 |
| DIARRHOEA | 25 |
How to read lifitegrast FAERS figures (WATCHLIST · DEATH-MARKED · HOSP-LIGHT)
FAERS holds 15,783 voluntary reports linked to lifitegrast (Xiidra), 2015-2025. Death is listed on 283 (1.8%). Hospitalization appears on 615 (3.9%). Top co-reported indication: Product Used For Unknown Indication.
Mid-volume extract - treat DEATH-MARKED · HOSP-LIGHT as signal-detection rates next to 83% of sex-coded reports are female (11,783 F / 2,442 M).
Read with lifitegrast
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-MARKED · HOSP-LIGHT stamps.
ABS(total_reports) peer at 15,757 FAERS cases (Δ 26 lighter vs lifitegrast); DEATH-HEAVY · HOSP-HEAVY · FEMALE-LED vs this page's WATCHLIST · DEATH-MARKED · HOSP-LIGHT · FEMALE-LED.
ABS(total_reports) peer at 15,755 FAERS cases (Δ 28 lighter vs lifitegrast); DEATH-HEAVY · HOSP-MID · SEX-BALANCED vs this page's WATCHLIST · DEATH-MARKED · HOSP-LIGHT · FEMALE-LED.
ABS(total_reports) peer at 15,846 FAERS cases (Δ 63 heavier vs lifitegrast); DEATH-MARKED · HOSP-MID · SEX-BALANCED vs this page's WATCHLIST · DEATH-MARKED · HOSP-LIGHT · FEMALE-LED.
ABS(total_reports) peer at 15,616 FAERS cases (Δ 167 lighter vs lifitegrast); DEATH-HEAVY · HOSP-HEAVY · FEMALE-LED vs this page's WATCHLIST · DEATH-MARKED · HOSP-LIGHT · FEMALE-LED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 60.3 pp vs lifitegrast's DEATH-MARKED): CASELOAD · HOSP-MID.
lifitegrast stamps WATCHLIST · FEMALE-LED; class peers and methodology beat restating the same FAERS caveats on every effects URL.